Capacity, funding and care

The pandemic created a natural experiment nobody wanted: months in which routine diagnosis and treatment stopped, followed by waiting lists at record length in England and elsewhere. The evidence on what that costs is arriving, and it is uneven. For cancer, modelling and now registry data show later-stage diagnosis and a measurable mortality effect for some sites; for cardiovascular disease, delayed presentation and missed treatment are visible in excess deaths at home in 2020 and 2021. For elective care the picture is murkier: long waits for joint replacement or cataract surgery cost function and quality of life more than life, and the studies that link waiting time to mortality mostly find small effects confounded by who waits. Emergency care is the newest strand: long waits in emergency departments are associated with higher mortality in the weeks after, in studies from England and elsewhere, and the estimates of deaths attributable to them are contested.

Behind the waits sit workforce and money. Health spending grew more slowly in the 2010s than in the decades before across most of the OECD, then jumped in the pandemic and is now flat in real terms in several countries; staff shortages are reported everywhere and measured comparably almost nowhere; bed numbers per head have fallen for decades by design. The cross-country evidence linking spending to outcomes is old and weak, and the natural experiments — austerity in some countries, expansion in others — have produced results that depend on the method.

England publishes waiting-time data of unusual detail, which is why so much of the evidence is English; other countries measure it differently or not at all. The question is whether capacity is a mortality story or a morbidity one, and for which conditions.

Every ageing society is renegotiating the same settlement, and the evidence is about which arrangements hold. Japan's mandatory long-term care insurance, running since 2000, has survived by raising premiums and tightening eligibility; Germany's has raised contributions repeatedly; the Netherlands spends more per head than almost anyone and is now trying to shift care home. England has abandoned a lifetime cap on care costs and commissioned another review, due to report in stages to 2028. Across countries the direction is the same: more care at home, more reliance on unpaid carers, and a workforce increasingly recruited from abroad. What the evidence does not yet show is outcomes. Spending and coverage are well measured; the health of people receiving care, and of those providing it unpaid, is not, and evaluations of funding reforms against those outcomes are rare. Hospital and social care are one system in the data as well as in life: the waits at the front door are made of the discharges at the back, and a country's care settlement decides how many beds its hospitals need.

Status

emerging

Direction

strengthening

Would change our view

A linked study attributing deaths to waiting time for a defined condition with proper adjustment; evidence that the pandemic-era cancer stage shift has reversed; or a cross-country study relating changes in spending or staffing to mortality with a credible design; an evaluation of a national care-funding reform showing a measurable effect on recipients' or carers' health, or the English review's final report.

Trackers

Gaps

Waiting-time data comparable across countries; any mortality linkage outside England and a few Nordic studies; primary-care access as distinct from hospital waits; workforce measured on a common basis; comparable measurement of unpaid care across countries; care outcomes beyond spending and coverage.